JP2015522576A - 血小板由来成長因子に結合する設計アンキリンリピートタンパク質 - Google Patents

血小板由来成長因子に結合する設計アンキリンリピートタンパク質 Download PDF

Info

Publication number
JP2015522576A
JP2015522576A JP2015519089A JP2015519089A JP2015522576A JP 2015522576 A JP2015522576 A JP 2015522576A JP 2015519089 A JP2015519089 A JP 2015519089A JP 2015519089 A JP2015519089 A JP 2015519089A JP 2015522576 A JP2015522576 A JP 2015522576A
Authority
JP
Japan
Prior art keywords
amino acid
ankyrin repeat
seq
repeat domain
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015519089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522576A5 (enExample
Inventor
バウマン，ミヒャエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Publication of JP2015522576A publication Critical patent/JP2015522576A/ja
Publication of JP2015522576A5 publication Critical patent/JP2015522576A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015519089A 2012-06-28 2013-06-27 血小板由来成長因子に結合する設計アンキリンリピートタンパク質 Pending JP2015522576A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12174020 2012-06-28
EP12174020.3 2012-06-28
PCT/EP2013/063488 WO2014001442A1 (en) 2012-06-28 2013-06-27 Designed ankyrin repeat proteins binding to platelet-derived growth factor

Publications (2)

Publication Number Publication Date
JP2015522576A true JP2015522576A (ja) 2015-08-06
JP2015522576A5 JP2015522576A5 (enExample) 2016-09-23

Family

ID=48699826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015519089A Pending JP2015522576A (ja) 2012-06-28 2013-06-27 血小板由来成長因子に結合する設計アンキリンリピートタンパク質

Country Status (16)

Country Link
US (2) US9163070B2 (enExample)
EP (1) EP2867360B1 (enExample)
JP (1) JP2015522576A (enExample)
KR (1) KR20150023957A (enExample)
CN (1) CN104508129A (enExample)
AU (1) AU2013283296A1 (enExample)
BR (1) BR112014032316A2 (enExample)
CA (1) CA2877584A1 (enExample)
HK (1) HK1209156A1 (enExample)
IL (1) IL236428A0 (enExample)
IN (1) IN2014MN02522A (enExample)
MX (1) MX2014015825A (enExample)
RU (1) RU2014150224A (enExample)
SG (1) SG11201408196RA (enExample)
WO (1) WO2014001442A1 (enExample)
ZA (1) ZA201408872B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN103459415B (zh) * 2010-11-26 2021-04-09 分子组合公司 设计的与血清白蛋白结合的重复蛋白
EP3646880A1 (en) 2012-05-07 2020-05-06 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
US10665324B2 (en) 2014-07-07 2020-05-26 Yeda Research And Development Co. Ltd. Method of computational protein design
US20170226158A1 (en) * 2014-08-11 2017-08-10 Medimmune Limited Intracellular antigen binding
CA2963723A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-pdgf-b antibodies and methods of use
WO2016075034A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
SG11201703458UA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Anti-ang2 antibodies and methods of use
AU2016240220B2 (en) 2015-04-02 2019-11-21 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
US10283384B2 (en) * 2015-04-27 2019-05-07 Taiwan Semiconductor Manufacturing Co., Ltd. Method for etching etch layer and wafer etching apparatus
ES2953516T3 (es) 2016-09-22 2023-11-14 Molecular Partners Ag Proteínas de unión recombinantes y su uso
US10037890B2 (en) * 2016-10-11 2018-07-31 Lam Research Corporation Method for selectively etching with reduced aspect ratio dependence
US11127483B2 (en) 2017-03-07 2021-09-21 Igc Bio, Inc. Computational pipeline for antibody modeling and design
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
CN111886338A (zh) 2018-03-22 2020-11-03 柏林夏瑞蒂医科大学 Crispr相关蛋白反应性t细胞免疫
WO2019238966A1 (en) 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
BR112021005670A2 (pt) 2018-10-08 2021-06-22 Universität Zürich polipeptídeos tetraméricos de ligação a her2
WO2020104627A1 (en) 2018-11-21 2020-05-28 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
US20220088144A1 (en) 2019-01-11 2022-03-24 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
US20220178926A1 (en) 2019-04-10 2022-06-09 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
CA3139051A1 (en) 2019-06-04 2020-12-10 Christian REICHEN Multispecific proteins
US20220242973A1 (en) * 2019-06-04 2022-08-04 Molecular Partners Ag Recombinant fap binding proteins and their use
CA3139041A1 (en) * 2019-06-04 2020-12-10 Christian REICHEN Recombinant 4-1bb binding proteins and their use
WO2021044050A1 (en) 2019-09-05 2021-03-11 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
WO2021116462A1 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
US20230151118A1 (en) 2020-04-06 2023-05-18 Universität Zürich Artc1 ligands for cancer treatment
TW202208404A (zh) 2020-05-06 2022-03-01 瑞士商分子組合公司 新穎錨蛋白重複結合蛋白質及其用途
BR112022023049A2 (pt) 2020-05-14 2022-12-20 Molecular Partners Ag Proteínas multiespecíficas
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
AU2021327147A1 (en) 2020-08-18 2023-04-06 Universität Zürich A CD25-biased anti-IL-2 antibody
JP2023554351A (ja) 2020-12-16 2023-12-27 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規の徐放性プロドラッグ
US20240310378A1 (en) 2021-02-11 2024-09-19 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
JP2024509904A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ
AU2022231913A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd33 engagers
US20240150475A1 (en) 2021-03-09 2024-05-09 Molecular Partners Ag Novel darpin based cd123 engagers
CA3227299A1 (en) 2021-08-05 2023-02-09 Immunos Therapeutics Ag Pharmaceutical compositions comprising hla fusion proteins
KR20240045260A (ko) 2021-08-05 2024-04-05 이뮤노스 테라퓨틱스 아게 Hla 융합 단백질을 포함하는 복합 치료제
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
CN119731200A (zh) 2022-08-01 2025-03-28 分子合作伙伴股份公司 经电荷修饰设计的重复结构域及其用途
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024133013A1 (en) 2022-12-19 2024-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Means and methods to target endogenous condensates
AU2024217729A1 (en) 2023-02-08 2025-08-21 Immunos Therapeutics Ag FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2025008519A1 (en) 2023-07-05 2025-01-09 Universität Bern Il-1ra blockers for treatment and prevention of sepsis
WO2025021293A1 (en) 2023-07-25 2025-01-30 Universität Zürich Disruption of rbr1 expression in plant cells
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025202503A1 (en) 2024-03-28 2025-10-02 Universität Zürich Extracellular vesicles carrying cancer specific splice variants

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508033A (ja) * 2000-09-08 2004-03-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
JP2005512962A (ja) * 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
JP2007503451A (ja) * 2003-08-27 2007-02-22 （オーエスアイ）アイテツク・インコーポレーテツド 眼血管新生疾患の治療のための併用療法
JP2012507271A (ja) * 2008-11-03 2012-03-29 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE69834032T2 (de) 1997-04-23 2006-12-07 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
ES2280131T3 (es) 1998-12-02 2007-09-01 Adnexus Therapeutics, Inc. Fusiones de adn-proteina y utilizaciones de las mismas.
BRPI0517834A (pt) * 2004-11-12 2008-10-21 Bayer Schering Pharma Ag vìrus da doença de newcastle recombinante
WO2006129828A2 (en) * 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Target substance capturing molecule
DE602006010386D1 (en) 2005-07-08 2009-12-24 Univ Zuerich Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden
WO2007103515A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
UY31504A1 (es) 2007-11-30 2009-07-17 Construcciones de union de antigenos
WO2009100990A1 (en) * 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Process for the production of a peptide
EP2263088A2 (en) * 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN103459415B (zh) * 2010-11-26 2021-04-09 分子组合公司 设计的与血清白蛋白结合的重复蛋白
WO2012149439A2 (en) * 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508033A (ja) * 2000-09-08 2004-03-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
JP2005512962A (ja) * 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
JP2007503451A (ja) * 2003-08-27 2007-02-22 （オーエスアイ）アイテツク・インコーポレーテツド 眼血管新生疾患の治療のための併用療法
JP2012507271A (ja) * 2008-11-03 2012-03-29 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H KASPAR BINZ, NATURE BIOTECHNOLOGY, vol. 22, no. 5, JPN6017019331, 2004, pages 575 - 582, ISSN: 0003566561 *
MICHAEL T. STUMPP, DRUG DISCOVERY TODAY, vol. Vol.13, No.15/16, JPN6017019335, 2008, pages 695 - 701, ISSN: 0003566562 *

Also Published As

Publication number Publication date
SG11201408196RA (en) 2015-03-30
MX2014015825A (es) 2015-08-10
IL236428A0 (en) 2015-02-26
ZA201408872B (en) 2016-05-25
BR112014032316A2 (pt) 2017-06-27
US20140005125A1 (en) 2014-01-02
CN104508129A (zh) 2015-04-08
CA2877584A1 (en) 2014-01-03
KR20150023957A (ko) 2015-03-05
RU2014150224A (ru) 2016-08-20
US20150368302A1 (en) 2015-12-24
EP2867360A1 (en) 2015-05-06
US9163070B2 (en) 2015-10-20
HK1209156A1 (en) 2016-03-24
WO2014001442A1 (en) 2014-01-03
EP2867360B1 (en) 2019-05-08
AU2013283296A1 (en) 2015-02-05
IN2014MN02522A (enExample) 2015-07-17

Similar Documents

Publication Publication Date Title
US9163070B2 (en) Designed ankyrin repeat proteins binding to platelet-derived growth factor
JP6105479B2 (ja) 血清アルブミンに結合する設計リピートタンパク質
US11453708B2 (en) Designed ankyrin repeat proteins binding to hepatocyte growth factor
RU2650765C1 (ru) Связывающие белки, ингибирующие взаимодействие vegf-a рецептора
RU2605309C2 (ru) Модифицированные связывающие белки, ингибирующие взаимодействие vegf-a рецептора
CN115003689A (zh) 具有改变的表面残基的经设计的锚蛋白重复结构域
CN115175691A (zh) 结合血清白蛋白的纤连蛋白iii型结构域及其应用
HK40059771A (en) Designed repeat proteins binding to serum albumin
US20120178682A1 (en) GB1 Peptidic Compounds and Methods for Making and Using the Same
HK40081011A (en) Serum albumin-binding fibronectin type iii domains and uses thereof
HK1238258B (zh) 抑制vegf-a受体相互作用的结合蛋白
HK1179876B (en) Modified binding proteins inhibiting the vegf-a receptor interaction

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160621

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160713

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180206